Valneva SE (0OB3.L) LSE

3.69

-0.036(-0.97%)

Updated at September 08 08:01AM

Currency In EUR

Valneva SE

Address

6 rue Alain Bombard

Saint-Herblain, 44800

France

Phone

33 2 28 07 37 10

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

713

First IPO Date

February 17, 2011

Key Executives

NameTitlePayYear Born
Mr. Thomas LingelbachPresident, Chief Executive Officer & Director999,1051963
Mr. Franck Grimaud MBAChief Business Officer454,1911967
Dr. Juan-Carlos Jaramillo M.D.Chief Medical Officer584,7751971
Ms. Dipal PatelChief Commercial Officer590,9491975
Mr. Peter BuhlerChief Financial Officer640,0211971
Ms. Kendra WerginGeneral Counsel & Corporate Secretary01986
Mr. Vincent DequenneChief Operating Officer01967
Dr. Hanneke Schuitemaker Ph.D.Chief Scientific Officer01964
Mr. Joshua Drumm Ph.D.Vice President of Investor Relations0N/A
Ms. Laetitia Bachelot-FontaineVice President of Global Communications & European Investor Relations0N/A

Description

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.